Indication
In combination with pomalidomide and dexamethasone (BPd) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy including lenalidomide.
Medicine details
- Medicine name:
- belantamab mafodotin (Blenrep)
- SMC ID:
- SMC2747
- Pharmaceutical company
- GlaxoSmithKline UK Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Publication due date:
- 13 October 2025
- SMC meeting date:
- 02 September 2025
- Patient group submission deadline:
- 30 June 2025